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Angiotensin (Ang) II stimulates plasminogen activator
inhibitor-1 (PAI-1) expression in many cell types by
mechanisms that are cell-type specific. We measured effects
of Ang II or norepinephrine on PAI-1 expression in wild type
(WT) and Ang type-1a receptor knockout mice (AT1a/) in
the presence or absence of the non-specific AT1 antagonist
losartan. Ang II and norepinephrine increased systolic blood
pressure equally, whereas losartan decreased the pressor
response of the former but not the latter in WT mice. In
AT1a/ mice, baseline systolic blood pressure was lower
with no effect of Ang II, norepinephrine, or losartan. Ang II
stimulated PAI-1 expression in the heart, aorta, and kidney
and markedly in the liver of WT mice. In AT1a/ mice,
Ang II-stimulated PAI-1 was significantly attenuated
compared with the WT in the heart and aorta but
significantly enhanced in the kidney. Losartan decreased the
induction in the aorta and liver of WT, and in the kidney and
liver of AT1a/ mice. Norepinephrine increased PAI-1
expression in WT heart and aorta, and in AT1a/ heart,
kidney, and liver with no effect of losartan. Renal PAI-1
expression correlated with AT1b receptor mRNA. We conclude
that Ang II stimulates PAI-1 expression in part through the
AT1b receptor in the kidney and liver. Further,
norepinephrine induces PAI-1 expression in vivo with AT1a
receptor deficiency modulating the effect.
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Activation of the renin–angiotensin–aldosterone system
causes vascular toxicity in part through effects of angiotensin
(Ang) II to induce the expression of plasminogen activator
inhibitor-1 (PAI-1),1,2 a major physiological inhibitor of
fibrinolysis, in vitro and in vivo.3 Increased PAI-1 has been
implicated in the pathogenesis of coronary arterial throm-
bosis and myocardial infarction in mouse models4 and with
increased risk of atherosclerotic thrombotic events in studies
in humans.5,6 In addition, by preventing the activation of
matrix metalloproteinases and the degradation of extracel-
lular proteins by plasmin, PAI-1 promotes fibrosis.7–10 In the
kidney, increased PAI-1 expression contributes to the
pathogenesis of both glomerular injury and tubulointerstitial
fibrosis.9,11,12
Ang II stimulates PAI-1 expression in vitro in a variety of
cell types including adipocytes, astrocytes, endothelial cells,
vascular smooth muscle cells (VSMCs), proximal tubular
epithelial cells, and mesangial cells.1,2,13–15 The mechanism
through which Ang II stimulates PAI-1 expression depends
on the cell type. For example, in endothelial cells and
proximal tubular epithelial cells, the effect of Ang II on PAI-1
expression appears to be at least partially mediated through
its hexapeptide metabolite angiotensin-3–8 (Ang IV).14,16,17
Thus, administration of pharmacological agents that block
the conversion of Ang II to Ang IV prevents the effect of Ang
II on PAI-1 expression. Similarly, Ang II-induced endothelial
PAI-1 expression is blocked by AT4 receptor antagonists, but
not by selective AT1 or AT2 receptor antagonists.
16 In
contrast, AT1 receptor antagonism decreases PAI-1 expression
in astrocytes, VSMCs, and adipocytes.2,13,15
Studies in the rat provide conflicting data as to whether
Ang II increases cardiovascular and renal PAI-1 expression
in vivo through the AT1 receptor or via conversion of Ang II
to Ang IV and activation of the AT4 receptor. We have
reported previously that AT1 receptor antagonism abolished
acute Ang II-induced hepatic, renal, aortic, and cardiac PAI-1
expression.18 Likewise, AT1 receptor antagonism decreased
Ang II-induced aortic and cardiac PAI-1 expression in
Sprague–Dawley rats.19 On the other hand, 2-week infusion
of either Ang II or Ang IV significantly increased
cardiac PAI-1 expression, whereas only Ang II increased
renal PAI-1 expression.20 However, none of these studies
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delineated the role of specific AT1 receptor subtypes in
Ang II-stimulated PAI-1 expression.
We therefore tested the hypothesis that Ang II induces
PAI-1 expression via the AT1a receptor in vivo. To do this, we
compared the effect of a 4-h infusion of Ang II or an
equivalent pressor dose of norepinephrine on cardiac, aortic,
renal, and hepatic PAI-1 expression in wild type (WT) mice
and in mice lacking the AT1a receptor (AT1a/), in the
presence and absence of the non-specific AT1 receptor
antagonist losartan.
RESULTS
Hemodynamic and aldosterone responses to agonists
Figure 1 illustrates the effect of Ang II or norepinephrine on
systolic blood pressure (SBP) in WT and AT1a/ mice.
Ang II (mean SBP over 4 h 125.975.2 mm Hg, P¼ 0.004
versus saline) or norepinephrine (mean SBP 127.074.4 mm
Hg, P¼ 0.002) significantly increased pressure compared
with normal saline (mean SBP 103.075.5 mm Hg) in the
WT mice. The pressor effects of Ang II and norepinephrine
were similar (P¼ 0.877). Pre-treatment with losartan sig-
nificantly decreased baseline SBP (Figure 1, P¼ 0.002) and
attenuated the SBP response to Ang II (mean SBP
108.877.4 mm Hg, P¼ 0.030 versus Ang II alone during
first 3 h, P¼ 0.530 versus saline) in WT mice. There was no
effect of losartan on the pressor response to norepinephrine
(mean SBP during norepinephrine and losartan
125.377.4 mm Hg). Baseline SBP was significantly lower in
AT1a/ mice compared to WT (Figure 1, Po0.001).
Moreover, there was no effect of either Ang II (P¼ 0.778)
or norepinephrine (P¼ 0.648) on SBP in AT1a/ mice.
Pre-treatment with losartan abolished the difference in
baseline SBP between WT and AT1a/ mice (P¼ 0.890);
there was no effect of losartan on SBP during Ang II or
norepinephrine in AT1a/ mice.
Table 1 shows the effect of treatment on plasma
aldosterone concentrations in WT and AT1a/ mice. Ang
II only numerically tended to increase aldosterone in WT
mice. However, aldosterone concentrations were significantly
higher in Ang II-infused WT mice compared with Ang II-
infused AT1a/ mice. In addition, losartan significantly
decreased aldosterone concentrations in Ang II- and
norepinephrine-infused WT mice, but did not significantly
affect aldosterone concentrations in AT1a/ mice.
PAI-1 mRNA expression and active PAI-1 antigen
Ang II increased PAI-1 expression in heart (9.9-fold,
Po0.001 versus saline), aorta (4.6-fold, Po0.05), kidney
(2.5-fold, Po0.05), and liver (97-fold, Po0.001), respec-
tively, of WT mice (Figure 2). Losartan attenuated Ang II-
induced PAI-1 expression in the aorta (1.8-fold, NS versus
saline) and liver (9.8-fold, Po0.01 versus Ang II alone). In
AT1a/ mice, Ang II-induced PAI-1 expression was
diminished in the heart (Po0.05 versus WT Ang II) and
aorta (Po0.05 versus WT Ang II), equivalent in the liver (43-
fold versus WT saline), but enhanced in kidney (9.1-fold
versus WT saline, Po0.05 versus WT Ang II) compared with
WT mice. Losartan attenuated Ang II-induced PAI-1
expression in the kidney (1.6-fold versus WT saline,
Po0.05 versus Ang II alone) and liver (11.9-fold, Po0.05
versus Ang II alone) of AT1a/ mice.
To determine whether the effect of Ang II on PAI-1
expression was pressor-dependent, we assessed whether
norepinephrine increased PAI-1 expression in WT or
AT1a/ mice. Norepinephrine increased PAI-1 expression
in the heart (15.6-fold) and aorta (7.4-fold) but not the
kidney or liver of WT mice. Even though norepinephrine did
not increase blood pressure, norepinephrine increased PAI-1
expression in heart (8.2-fold versus WT saline, Po0.001),
kidney (7.7-fold, Po0.01), and liver (50.9-fold, Po0.001) in
AT1a/ mice. Losartan did not affect norepinephrine
induced PAI-1 expression. To determine whether norepi-
nephrine induced PAI-1 mRNA expression via an effect on
TGF-b expression, we measured TGF-b mRNA expression in
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Figure 1 | Systolic blood pressure (SBP) response to treatment in
WT and AT1a/ mice. Infusion of either angiotensin II (Ang II,
P¼ 0.004) or norepinephrine (P¼ 0.002) significantly increased SBP
compared with normal saline in the WT mice. The pressor effects of
Ang II and norepinephrine were similar in WT mice (P¼ 0.877).
Losartan blunted the pressor effect of Ang II, but not norepinephrine.
Baseline blood pressure was significantly lower in AT1a/ mice
compared to WT mice. There was no effect of losartan, Ang II, or
norepinephrine on SBP in the AT1a/ mice.
Table 1 | Effect of treatment on plasma aldosterone
concentrations
Wild type AT1a/
Vehicle 512.97273.4 246.5754.9
Ang II 616.4773.8 352.9780.6*
Ang II+losartan 158.6743.7w,z 199.8710.7
Norepinephrine 595.77 81.3 431.27107.1
Norepinephrine+losartan 124.6718.1w,z 294.2796.8
Plasma aldosterone concentrations are given in pg/ml.
*Po0.05 versus wild type Ang II, wPo0.05 versus wild type Ang II, zPo0.05 versus
wild type norepinephrine.
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the heart, kidney, and liver (Table 2). Norepinephrine did not
increase TGF-b expression in any organ in WT or AT1a/
mice. TGF-b expression was similar in the heart of WT and
AT1a/ mice. TGF-b expression was decreased in the liver
of AT1a/ mice compared with WT mice, regardless of
treatment. On the other hand, renal TGF-b expression was
increased in saline-treated and norepinephrineþ losartan-
treated AT1a/ mice compared with WT mice. Renal TGF-b
mRNA expression correlated with renal PAI-1 expression in
AT1a/ mice (r¼ 0.783, Po0.001), but not in WT mice
(r¼ 0.194, P¼ 0.441). However, there was no relationship
between relative renal pSmad2 protein, a marker of TGF-b
signaling, and renal PAI-1 expression (P¼ 0.582).
Ang II also significantly increased circulating active
plasma PAI-1 antigen in WT and AT1a/ mice and losartan
prevented this effect (Figure 3). Norepinephrine significantly
increased interleukin (IL)-6 and active PAI-1 antigen in
AT1a/ mice, but not in WT mice. Circulating active
plasma PAI-1 antigen concentrations correlated with
renal (r¼ 0.904, Po0.001) and hepatic (r¼ 0.731,
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Figure 2 | Effect of saline, Ang II, and norepinephrine (NE) infusions on PAI-1 expression as measured by RT-PCR in heart, aorta,
kidney, and liver of WT and AT1a/ mice. *Po0.01 versus WT saline, wPp0.001 versus WT saline, zPo0.05 versus AT1a/ saline, yPp0.05
versus the same treatment in WT, ||Pp0.001 versus AT1a/ saline, zPo0.05 versus WT saline, #Po0.01 versus AT1a/ saline, **Po0.05 versus
AT1a/ Ang II, wwPo0.01 versus same treatment in WT, zzPo0.01 versus WT Ang II.
Table 2 | Effect of treatment on TGF-b mRNA expression
Relative mRNA expression PSmad2/a-tubulin protein
Wild type AT1a P-value Wild type AT1a P-value
Heart
Saline 1.0570.20 0.8970.18 NS
Ang II 0.8070.10 0.5770.20 NS
Ang II+losartan 0.7670.08 0.4570.08* NS
NE 1.1270.24 0.7970.24 NS
NE+losartan 0.8370.19 0.8370.19 NS
Kidney
Saline 1.0070.06 1.6970.41 0.008 0.8270.22 0.4570.06 NS
Ang II 0.7970.11 0.8670.18w NS 0.8570.14 0.5970.10 NS
Ang II+losartan 1.2970.07 0.7570.06w 0.026 0.7170.13 1.0270.23* NS
NE 0.8570.17 1.1670.07* NS 0.8170.13 0.6670.12 NS
NE+losartan 0.5270.06* 1.0970.16* 0.020 0.9470.11 0.7770.11 NS
Liver
Saline 1.0070.08 0.1670.05 0.012
Ang II 0.8870.14 0.3170.12 0.050
Ang II+losartan 0.8370.09 0.1770.07 0.043
NE 0.7370.32 0.1470.02 0.030
NE+losartan 0.7370.39 0.1170.02 0.057
NS, not significant.
*Po0.05 versus saline, wPp0.001 versus saline.
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Po0.001) PAI-1 expression. In addition, IL-6 (r¼ 0.632,
P¼ 0.006) and active PAI-1 antigen (r¼ 0.666, P¼ 0.003)
correlated with plasma aldosterone concentrations in AT1a/
mice, but not in WT mice. After controlling for losartan
treatment, PAI-1 mRNA expression in the kidney of AT1a/
mice also correlated significantly with circulating aldosterone
(r¼ 0.433, P¼ 0.04). There was no correlation between renal
PAI-1 expression and aldosterone in WT mice. There was no
correlation between cardiac, hepatic, or aortic PAI-1 mRNA
expression and aldosterone in either strain.
AT1a and AT1b receptor expression
To determine whether differences in patterns of PAI-1 mRNA
expression in the kidney and liver of WT and AT1a/ mice
resulted from differences in expression of the AT1b receptor,
we measured AT1a and AT1b receptor mRNA expression. In
WT mice, Ang II decreased AT1a receptor expression in the
kidney and liver, even during losartan (Table 3). Norepi-
nephrine alone also decreased AT1a receptor expression in
WT mice. As expected, AT1a receptor mRNA expression was
reduced to artifactual levels in the AT1a/ mice. Renal and
hepatic AT1b receptor expression was statistically similar in
WT and AT1a/ mice. However, the relationship between
AT1b receptor and PAI-1 mRNA expression differed in the
kidneys of WT and AT1a/ mice. Thus, while renal PAI-1
mRNA expression correlated with AT1b receptor expression
in both WT (r¼ 0.767, Po0.001) and AT1a/ (r¼ 0.514,
P¼ 0.020) mice, the slope of the relationship was signifi-
cantly steeper in the AT1a/ mice (slope 6.8 versus 0.5,
Po0.001). Hepatic PAI-1 expression did not correlate with
AT1a or AT1b receptor expression in WT or AT1a/ mice.
Localization of PAI-1 expression by in situ hybridization
Figures 4 and 5 show the effect of saline, Ang II, and
norepinephrine on PAI-1 mRNA signal in the heart and aorta
from WT and AT1a/ mice. Hybridization with control
sense probes showed no specific signal. There was minimal
expression of PAI-1 mRNA in cardiac myocytes and aorta by
in situ hybridization in saline-infused WT or AT1a/ mice.
In Ang II-treated WT mice, PAI-1 mRNA signal was increased
(2–3þ ) in the myocytes of the left ventricle and septum as
well as in aortic smooth muscle cells (2–3þ ) and aortic
endothelium (1þ ). In contrast, in AT1a/ mice, Ang II
infusion induced a variable, but overall modest (1–3þ )
increase in PAI-1 expression in the endocardium, but not in
ventricular myocytes. Only trace PAI-1 mRNA signal was
observed in aortae from Ang II-infused AT1a/ mice.
Infusion of norepinephrine induced a strong (3–4þ )
increase in PAI-1 mRNA signal in the myocytes of the left
ventricle, a 1þ increase in signal in the myocytes of the right
ventricle, and a 1–2þ increase in PAI-1 mRNA signal in the
endocardium of hearts from WT mice; there was also a 1–2þ
increase in PAI-1 mRNA signal in the vascular smooth
muscle and endothelium of the aorta. Norepinephrine
induced a 2þ increase in PAI-1 mRNA signal in the
endocardium of AT1a/ mice, with focal areas of increased
PAI-1 mRNA signal in the left ventricle, with only trace signal
in the aorta.
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Figure 3 | Effect of saline, Ang II, and norepinephrine (NE) infusions on plasma PAI-1 (left) and IL-6 (right) concentrations. *Po0.05
versus WT saline, wPo0.005 versus WT saline, zPo0.01 versus WT NE, yPo0.05 versus WT NEþ losartan, ||Po0.05 versus any WT group, zPo0.05
versus AT1a/ Ang II losartan.
Table 3 | Effect of treatment on AT1a and AT1b receptor mRNA
expression
Relative mRNA expression Wild type AT1a P-value
Kidney
AT1a receptor
Saline 0.8370.08 0.0570.01 o0.001
Ang II 0.4870.10* 0.0470.02 0.006
Ang II+losartan 0.6070.08w 0.0470.00 0.002
NE 0.6070.04w 0.0770.02 o0.001
NE+losartan 1.2070.04* 0.0570.01 o0.001
AT1b receptor
Saline 1.1370.36 1.9271.22 NS
Ang II 3.3471.30z,y,8,z 1.0470.46 NS
Ang II+losartan 1.2670.20 0.6270.11 0.029
NE 0.4870.06 0.6170.07 NS
NE+losartan 0.5970.18 0.7470.15 NS
Liver
AT1a receptor
Saline 1.0370.07 0.0270.01 o0.001
Ang II 0.9370.14 0.0170.01 0.003
Ang II+losartan 0.5770.14z 0.0770.06 0.03
NE 0.5570.09w 0.0170.00 0.001
NE+losartan 0.6270.19 0.0070.00 0.03
AT1b receptor
Saline 1.5771.04 0.5270.05 NS
Ang II 0.3170.10 0.6070.53 NS
Ang II+losartan 0.5770.12 0.3070.06 NS
NE 2.8972.75 0.2370.03 NS
NE+losartan 12.85712.82 0.2670.11 NS
NE, norepinephrine; NS, not significant.
*Po0.001 versus saline, wPo0.01 versus saline, zPo0.05 versus saline, yPo0.05
versus Ang II+losartan, 8Po0.001 versus NE, zPo0.005 versus NE+losartan.
Kidney International (2007) 72, 72–81 75
NJ Brown et al.: AT1 receptor and PAI-1 o r i g i n a l a r t i c l e
Figure 6 shows the effect of saline, Ang II, and
norepinephrine on PAI-1 mRNA expression in the kidney
from WT and AT1a/ mice. During saline infusion, there
was strong PAI-1 expression in the glomeruli of AT1a/,
but not WT, mice. Ang II induced mild diffuse expression of
PAI-1 in the kidney of both WT and AT1a/ mice with 2þ
increase in signal in the mesangium of AT1a/ animals.
Norepinephrine induced strong signal in the main renal
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Figure 4 | Effect of saline, Ang II and norepinephrine on PAI-1 expression by in situ hybridization in heart (original magnification
 400). There was minimal PAI-1 expression in the heart in saline-infused WT mice (a) or AT1a/ mice (e). Ang II increased PAI-1 expression
markedly in cardiac myocytes in the left ventricle and septum in WT mice (b). Pretreatment with losartan attenuated the effect of Ang II on PAI-1
signal in WT mice (c). Norepinephrine stimulated strong PAI-1 expression in cardiac myocytes in the left ventricle of WT mice, with moderate
endocardial signal and mild induction in right ventricle myocytes (d). Ang II induced only a modest signal for PAI-1 in AT1a/ mice (f).
Norepinephrine caused strong endocardial induction of PAI-1 AT1a/ mice (arrow), with focal signal in left ventricle myocytes (*) (g).
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Figure 5 | Effect of saline, Ang II, and norepinephrine on PAI-1 expression by in situ hybridization in aorta (original magnification
 400). There was minimal PAI-1 expression in the aorta in saline-infused WT mice (a) or AT1a/ mice (e). Ang II stimulated a marked increase
in PAI-1 expression in aortic VSMCs and a modest increase in aortic endothelium in WT mice (b). This was attenuated by pretreatment
with losartan (c). Norepinephrine induced strong PAI-1 expression in aortic vascular smooth muscle and endothelium of WT mice (d). Only trace
PAI-1 aortic signal was observed in Ang II-treated (f) or norepinephrine-treated (g) AT1a/ mice.
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artery and its major branches in both WT and AT1a/,
whereas norepinephrine also increased PAI-1 focally in
peritubular capillaries in the AT1a/ animals. Following
saline, the liver (not shown) of both WT and AT1a/ mice
showed similar very low-level diffuse PAI-1 signal. Ang II and
norepinephrine induced intense signal in centrilobular
hepatocytes in both WT and AT1a/ mice.
DISCUSSION
To test the hypothesis that Ang II stimulates PAI-1 expression
via the AT1a receptor in vivo, we studied the effect of genetic
AT1a deficiency and pharmacological AT1 receptor blockade
on PAI-1 expression. The data suggest that Ang II regulates
PAI-1 expression in the heart and aorta primarily via the AT1a
receptor, whereas the AT1b receptor contributes significantly
to Ang II-stimulated PAI-1 expression in the kidney and liver.
In addition, this study provides the first evidence that
norepinephrine regulates tissue PAI-1 expression in vivo.
AT1a receptor deficiency was associated with decreased
basal PAI-1 expression in the heart and aorta, but not in the
kidney or liver. These data concur with the data of Tsujino
et al.,21 who reported that the effect of AT1a deficiency on
circadian PAI-1 expression differs in an organ-specific
fashion. In that study, the investigators found depressed
trough PAI-1 expression in the heart and a lack of circadian
variation in PAI-1 expression in the aorta of AT1a/ mice,
whereas hepatic PAI-1 expression continued to exhibit
circadian rhythm and there was no difference in PAI-1
expression in the kidney of AT1a/ versus WT mice.
Previous studies using pharmacological receptor antago-
nists have consistently demonstrated that Ang II induces PAI-1
expression in vitro in cardiomyocytes22 and VSMCs22,23 and
in vivo18,20,22 in the heart and aorta via its AT1 receptor. A
recent study in cultured VSMCs from AT1a/ suggests that
Ang IV also induces PAI-1 expression in VSMCs. In this study,
Ang II-induced cardiac and aortic PAI-1 expression was
dramatically attenuated in AT1a/ mice, indicating that the
AT1a receptor primarily mediates increased cardiac and aortic
PAI-1 expression in this in vivo model.24 In contrast, the
finding in kidney and liver that Ang II-induced PAI-1
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Figure 6 | Effect of saline, Ang II, and norepinephrine (NE) in the presence and absence of losartan on PAI-1 expression by in situ
hybridization in kidney (original magnification  400). There was no effect of saline treatment on PAI-1 signal in WT mice (a). (b) Ang II
induced mild diffuse expression in WT mice, (c) which was similar during losartan treatment. (d) There was no effect of norepinephrine (e) or
norepinephrine þ losartan on PAI-1 signal in WT mice. (f) PAI-1 signal was mildly and diffusely increased in saline-treated AT1a/ mice
compared with (k) untreated, age-matched WT control. (g) Ang II induced PAI-1 expression in the mesangium of AT1a/ mice (h) and this
was attenuated after losartan. (i) Norepinephrine induced PAI-1 signal in the mesangium and peritubular capillaries in AT1a/ mice, (j) even in
the presence of losartan.
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expression was increased or preserved in AT1a/ mice and
that pharmacological AT1 receptor antagonism abolished this
expression indicates that the AT1b receptor contributes to the
regulation of PAI-1 expression in these organs. Indeed, the
relationship between PAI-1 and AT1b receptor mRNA expres-
sion was enhanced in AT1a/ compared with WT mice. In
addition, the localization of PAI-1 signal to peritubular
capillaries in the norepinephrine-treated AT1a/ mice is in
proximity to the tubular localization of AT1b receptors by
immunohistochemistry.25 These findings are compatible with
prior data indicating that non-specific pharmacological AT1
receptor antagonism18 decreases PAI-1 expression in these
organs.
We also report that norepinephrine-induced PAI-1
expression in the heart and aorta of WT mice and the heart
of AT1a/ mice. Of note, AT1a deficiency unmasked an
effect of norepinephrine on PAI-1 expression in the kidney
and liver, while at the same time the pressor response to
norepinephrine was blunted. This study did not specifically
address the mechanism through which norepinephrine
increases PAI-1 expression. Norepinephrine increases cardi-
omyocyte expression of TGF-b in male Sprague–Dawley
rats26 and enhances the effect of TGF-b on PAI-1 expression
in cardiac fibroblasts;27 however, we did not find a
stimulatory effect of acute (4 h) Ang II or norepinephrine
on TGF-b expression in any organ in either WT or AT1a/
mice. Although constitutive TGF-b mRNA expression was
increased in the kidney of AT1a/ mice compared with WT
mice and renal PAI-1 expression correlated with TGF-b
expression, the lack of correlation between PSmad2, a
downstream marker of TGF-b activation, and renal PAI-1
expression, suggests that increased TGF-b expression did not
account for norepinephrine-induced PAI-1 expression in the
AT1a/ mice.
Interruption of the renin–angiotensin–aldosterone system
reduces interstitial fibrosis and glomerulosclerosis.28,29 Prior
studies indicate that Ang II induces PAI-1 expression in the
heart and kidney in part through effects on endogenous
aldosterone and that mineralocorticoid receptor antagonism
can cause regression of existing glomerulosclerosis.30–32 In
this study, aldosterone concentrations were preserved in
vehicle and norepinephrine-treated AT1a/ mice. This is
consistent with data indicating that aldosterone synthesis
may occur via AT1b receptor stimulation, as well as via Ang
II-independent pathways, in AT1a/ mice.33,34 Increased
aldosterone concentrations were associated with increased
inflammation as measured by the cytokine IL-6. The
correlation between PAI-1 antigen concentrations or renal
PAI-1 mRNA expression and aldosterone suggests that
endogenous aldosterone contributed to PAI-1 expression in
AT1a/ mice. Given the profibrotic effects of PAI-1, this
finding is particularly intriguing in the context of recent
studies implicating aldosterone in cardiovascular remodeling
in AT1a-deficient mice. For example, Katada et al.
34 have
reported that endogenous aldosterone contributes to fibrosis
following myocardial infarction in AT1a/ mice. In an as
yet unpublished study, Kagayami et al. (abstract, Hyperten-
sion 2006) have observed that AT1a/ mice demonstrate
increased sensitivity to aldosterone/salt-induced cardiac
fibrosis.
To assess the pressor-dependence of Ang II-stimulated
PAI-1 expression, we determined the effect of equivalent
pressor doses of Ang II and norepinephrine on PAI-1
expression in WT mice. Unexpectedly, AT1a/ mice were
protected against the pressor effects of both norepinephrine
and Ang II. The renin–angiotensin–aldosterone system and
sympathetic system interact at many levels. Ang II facilitates
norepinephrine release at nerve endings35 and also increases
expression of the norepinephrine transporter through its AT1
receptor.36 In addition, crosstalk between the AT1 and a1-
adrenergic receptors and between AT1 and b-adrenergic
receptors has been described in rat and mouse cardiomyo-
cytes and in vivo.37,38 Prior studies in pithed rats indicate that
pharmacological AT1 receptor antagonism reduces the
pressor response to norepinephrine.39,40 More recently,
Raasch et al.41 reported that AT1 receptor antagonism
decreased vascular sensitivity to norepinephrine via a
mechanism involving both neuronal norepinephrine uptake
and presynaptic a2-mediated autoinhibition. To our knowl-
edge, this study is the first to demonstrate an attenuated
pressor response to norepinephrine in AT1a receptor-deficient
mice.
In summary, this study provides new evidence for tissue-
dependent roles of the AT1a and AT1b receptors in regulating
Ang II-stimulated PAI-1 expression in vivo. Ang II stimulates
PAI-1 expression primarily via the AT1a receptor in the heart
and the aorta, but via the AT1b receptor in the kidney and
liver. The study provides novel data supporting physiological
interaction between the renin–angiotensin–aldosterone sys-
tem and adrenergic system in regulating vascular tone and
PAI-1 expression. Norepinephrine-induced PAI-1 expression
could contribute to the variable effect of AT1 receptor
antagonism on PAI-1 concentrations observed in clinical
studies.42,43
MATERIALS AND METHODS
WT C57BL/6 and homozygous AT1a/ mice bred on a C57BL/6
background were studied. In a first experiment, 8-week-old male
AT1a/ mice were offspring of AT1aþ / mice maintained at
Vanderbilt since 1995. Twelve WT and 12 AT1a/ mice were
randomized to each of three treatment groups (n¼ 4 each):
intravenous saline, intravenous Ang II, and intravenous norepi-
nephrine. The experiment was repeated in the presence or absence of
the AT1 receptor antagonist losartan. In this latter experiment,
AT1a/ mice were obtained from the Jackson Laboratory
(B6.129P2-Agtr1tm1UNC/J; Bar Harbor, ME, USA). Twenty-five male
WT and 25 AT1a/ mice were randomized to treatment arms
(n¼ 5 each): intravenous saline, intravenous Ang II, oral losar-
tanþ intravenous Ang II, intravenous norepinephrine, and oral
losartanþ intravenous norepinephrine. All animal procedures were
approved by the Vanderbilt University Institutional Animal Care
and Use Committee.
Mice were anesthetized, and silicone and polyethylene cannulae
were placed in the jugular vein and carotid artery for continuous
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infusion and monitoring of arterial blood pressure, respectively.
These cannulae were passed under the skin and out through the
nape and fixed with sutures. Mice were allowed to recover and
infusion catheters were flushed every other day with physiological
saline containing 200 IU heparin/ml and 1 mg ampicillin/ml.
Animals randomized to losartan were given losartan in the drinking
water (1 mg/ml) beginning after catheter placement. Infusion
studies were performed 3 days postcatheter placement. Agonists or
saline were infused through the venous catheter for 4 h at a rate of
1.375 ml/min. Ang II was infused at a dose of 600 ng/kg/min, a dose
previously shown to increase PAI-1 expression in the rat and
mouse.18,44 Norepinephrine was infused at 12 mg/kg/min, a dose
chosen to cause a pressor response similar to that seen with Ang II.
Blood pressure was measured via carotid artery catheter throughout
infusions. Mice were killed immediately after the 4-h infusion and
the aorta, heart, liver, and kidney were harvested. Tissues for in situ
hybridization were immersion-fixed in 4% paraformaldehyde–pho-
sphate-buffered saline solution. The remainder of the heart, aorta,
kidney, and liver was frozen immediately in liquid nitrogen (LN2)
and stored at 801C until mRNA analysis. Aortae were collected into
RNAlaters solution (Ambion, Austin, TX, USA), stored at 41C
overnight, and then transferred to a vial for storage at 801C
until assay.
Biochemical assays
Aldosterone was determined using a radioimmunoassay utilizing
125I-aldosterone (MP Biomedicals, Irvine CA, USA), a primary
antibody to aldosterone (NIDDK National Hormone & Peptide
Program, Torrance, CA, USA), and a secondary anti-rabbit g-
globulin antibody (Linco Research, St Charles, MO, USA). Active
murine plasma PAI-1 (Molecular Innovations, Southfield, MI, USA)
and plasma IL-6 (R&D Systems Inc., Minneapolis, MN, USA) were
measured using commercially available enzyme-linked immunosor-
bent assay kits.
Oligonucleotide primers for reverse transcription–polymer-
ase chain reaction (RT-PCR)
Oligonucleotide primers were designed to complement mRNA
sequences reported in the GenBank database (murine PAI-1
[forward (50-TCCTCATCCTGCCTAAGTTCTC), reverse (50-GTGC
CGCTCTCGTTTACCTC)), TGF-b1 (forward (50-GCAACATGTGG
AACTCTACCAG), reverse (50-GACGTCAAAAGACAGCCACTCA)),
AT1aR (forward (5
0-TTTCCAGATCAAGTGCATTTTGA), reverse
(50-AGAGTTAAGGGCCATTTTGCTTT)); AT1b (forward (50-ACTG
GCAGAAATACCATGTCTTCA), reverse (50-CCGACTAATTATGTT
CATGTGGAAA)), and glyceraldehyde-3-phosphate dehydrogenase
(forward (TGAGGCCGGTGCTGAGTATGTCG) and reverse (CCAC
AGTCTTCTGGGTGGCAGTG-30)). For initial verification of these
products, one sample of each amplicon was sequenced by cycle
sequencing using dye terminators (BigDye Terminators, Perkin-
Elmer Applied Biosystems, Waltham, MA, USA) on an ABI Prism
310 Genetic Analyzer (Perkin-Elmer Applied Biosystems). The
specificity of all subsequent reactions was verified by first-derivative
melting curve analysis.
Quantitative RT-PCR
Relative quantification of mRNA was done by one-step RT-PCR
with real-time amplicon detection with the fluorescent dye SYBR
Green I on a LightCycler Instrument (Roche Applied Science,
Indianapolis, IN, USA), as described previously.44 RT-PCR was
performed in a reaction volume of 20 ml with 500 nmol/l each
primer for a series of twofold template dilutions from 1:1 to 1:16,
corresponding to 10.0–0.625mg/l total RNA. For reaction buffer and
RT-PCR enzymes, the LightCycler RNA Amplification Kit SYBR
Green I (Roche Applied Science) was used. After reverse transcrip-
tion at 551C for 10 min and an initial denaturation step at 951C for
30 s, amplification was performed with 50 cycles of denaturation
(951C for 1 s), annealing (631C for 10 s), and extension (721C for
20 s). To monitor amplification in real-time, double-strand DNA-
dependent SYBR Green I fluorescence was measured at the end of
the extension period of each cycle. For each transcript, an inverse
correlation was observed between the amount of applied total RNA
and the interpolated cycle number (C) at which the magnitude of
fluorescence increased with maximum velocity. The slope (m) and y
intercept (b) defining this relationship were calculated by linear
regression on the equation C¼m log (g total RNA)þ b, with
excellent goodness of fit (R240.98) obtained for all dilution series.
The average ratio of PAI-1 (or other gene of interest)/glyceralde-
hyde-3-phosphate dehydrogenase transcript observed in samples
obtained from each mouse was normalized to the average ratio of
the transcript observed in samples obtained from saline-treated WT
mice.
In situ hybridization
35S-labeled sense and antisense riboprobes for PAI-1 were prepared
by transcription of the pCRTMII plasmid with insertion of the cDNA
fragment by SP6 or T7 RNA polymerase (Promega, Madison, WI,
USA). Sections were dewaxed in xylene and hydrated in graded
ethanols and then phosphate-buffered saline. After treatment by
proteinase K and triethanolamine/acetic anhydride, sections were
dehydrated in ethanol and air-dried. Hybridization was done in
buffer (40% formamide, 10% dextran sulfate, 8 mmol/l dithiothrei-
tol, 0.2 mg/ml tRNA, 300 mmol/l NaCl, 10 mmol/l Tris–HCl,
5 mmol/l ethylenediaminetetraacetic acid, 0.02% polyvinylpyroli-
done, 0.02% Ficoll, and 0.02% bovine serum albumin) overnight at
501C. Sections were washed in 5 SSC, 20 mmol/l b-mercaptoetha-
nol at 501C for 15 min, in 2 SSC, 50% formamide at 651C for
20 min, in 0.1 M Tris-Hcl (pH 8.0), 0.01 M EDTA, 0.1 M Nacl (TEN)
twice at 371C for 10 min, treated with RNase at 371C for 30 min,
washed in TEN at 371C for 10 min, in 2 SSC and 0.1 SSC each
twice at 651C for 15 min. Sections were then dehydrated in ethanol
and air-dried, dipped in photographic emulsion, and exposed at 41C
for 14 days. The sections were developed with D-19 developer
(Eastman Kodak, Rochester, NY, USA) and counterstained with
Toluidine Blue. In situ expression was examined without knowledge
of the treatment group assignments, and overall intensity of signal
was semiquantitatively scored on a 0–3þ scale, where 0 is no
significant expression, 1þ is mild signal, 2þ is moderate signal,
and 3þ is intense signal. Localization of signal was also evaluated.
Western blotting for phospho-Smad 2
Frozen kidney tissues were homogenized in radioimmunoprecipita-
tion buffer (Boston BioProducts, Worcester, MA, USA) containing
150 mM NaCl, 50 mM Tris–HCl, pH 7.4, 5 mM ethylenediamine
tetraacetic acid, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate, 1 mM phenylmethyl sulfonyl fluoride,
phosphatase inhibitor cocktail 1 and 2 (Sigma, St Louis, MO,
USA), and proteinase inhibitor cocktail tablet (Roche Applied
Science) on ice. The protein concentration was measured using the
BCATM Protein Assay kit (Pierce, Rockford, IL, USA). Sample protein
(80mg) were loaded and separated by 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred into a 0.2-mm
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nitrocellulose membrane. Phospho-Smad-(pSmad)2 was detected
with a specific rabbit anti-PSmad2 polyclonal antibody (Upstate
Technology, Charlotte, VA, USA) at 1:500 dilution, and a-tubulin
was detected by monoclonal anti-a-tubulin antibody at 1:10 000
dilution (Abcam, Cambridge, MA, USA) overnight at 41C.
Secondary antibody was added after washing and incubated at
room temperature for 1 h. Protein bands on Western blots were
visualized by ECL PlusTM (GE Healthcare, Piscataway, NJ, USA) and
exposure to imaging film (Eastman Kodak). Expression of PSmad2
was quantified as the ratio of specific staining to a-tubulin.
Statistics analysis
Data are presented as means7s.e.m. Because responses to Ang II
and norepinephrine were statistically similar in the two experiments,
data from the experiments were combined for analysis. The effect of
treatment on SBP was analyzed using a general linear model in
which the within-subjects factor was time and the between-subjects
factors were mouse strain and treatment. Results were confirmed
using non-parametric methods. Comparisons of the ratios of PAI-1
(AT1a receptor, AT1b receptor, or TGF-b)/glyceraldehyde-3-phos-
phate dehydrogenase transcript among and between groups were
made using a Kruskal–Wallis or Mann–Whitney test, as appropriate.
A Po0.05 was considered significant.
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